Professor Holden recounted his exciting work with stent trials, as well as innovative aneurysm trials using the "radically different" Nellix EndoVascular Aneurysm Sealing device (Endologix). He also touched upon heavily calcified lesions, and the concept of 'leaving nothing behind' by using drug-eluting technologies and biodegradable scaffolds.
Renal denervation for treatment-resistant hypertension was the focus when Professor Scheinert met Professor Sievert, in particular how Symplicity HTN-3 has changed the face of the field. Will newer devices hold the answer?
Dr Ansel spoke about his research projects, in particular DCBs, covered stents, and his feelings about treating patients with drug-eluting technologies, and giving our best value care. He also addressed the question, are venous interventions "real or hype?"
Professor Dake focussed primarily on the future of drug-eluting stents and balloons, and the importance of collecting longer-term follow-up data. Reimbursement issues, the status of venous interventions – not to mention his penchant for Leipzig art – were also discussed.
A vascular surgeon from Australia, Dr Varcoe heads up the VERVE Symposium, in conjunction with the LINC Australia programme. Professor Scheinert asked him about what to expect from the upcoming Symposium in Sydney in December, as well as his perspectives on the innovative techniques performed by his Australian peers, and his thoughts on new technologies such as biodegradable stents.
Professor Torsello spoke about his new role as President of the German Society for Vascular Surgery, as well as his experience in leading an innovative vascular centre in Münster, Germany, split between two sites with different specialities and focus. Professor Torsello also commented on the training of young vascular surgeons in both open and endovascular techniques. But how should training be structured? Should every hospital have a hybrid suite?